Endovia Health Sciences, Inc. (EDVA): Unregistered Sales of Equity Securities
Endovia Health Sciences, Inc. (EDVA) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities. On August 25, 2026, Endovia Health Sciences, Inc. (the “Company”) sold and issued a total of 510,951 shares of common stock pursuant to that certain Securities Purchase Agreement dated September 19, 2025 with C/M Capital Master F
How this was made
The 30-second read
Why it matters
The capital raise provides modest cash for ongoing operations but introduces slight dilution.
Market read
Primary disclosure of a micro‑cap equity sale; limited immediate trading relevance.
What to watch
Potential future financing needs if the company cannot secure larger funding.
Background
Endovia Health Sciences is a clinical‑stage biotech company. The filing discloses a private placement under Rule 506(b).
Ticker impact
Endovia Health Sciences filed an 8‑K reporting the sale of 510,951 shares for $107,610.62, a primary disclosure of an unregistered equity sale.
Potential slight downward pressure due to dilution, but amount is small.
The transaction size is modest relative to typical capital raises, so market reaction is likely muted.
Market effects
No significant sector impact; micro‑cap biotech financing.
Limited to U.S. over‑the‑counter biotech investors.
Low
Counterpoint
The small raise may be viewed as a sign of cash constraints, suggesting caution.
Key entities
- InvestorC/M Capital Master Fund, LP
Purchaser of the 510,951 shares.
